Base de dados : HANSEN
Pesquisa : RIFAMPINA/ADMIN [Descritor de assunto]
Referências encontradas : 43 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 43 HANSEN  
              next record last record
seleciona
para imprimir
Id:27305
Autor:Mane, Ibrahima; Cartel, Jean-Louis; Grosset, Jacques-Henri.
Título:Field trial on efficacy of supervised monthly dose of 600mg rifampin, 400mg ofloxacin and 100mg minocycline for the treatment of leprosy; first results.
Fonte:Int. J. Lepr;65(2):224-229, Jun. 1997. tab.
Resumo:In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial, 220 patients with active leprosy (newly detected or relapsing after dapsone monotherapy) were recruited: 102 paucibacillary (PB) (60 males and 42 females) and 118 multibacillary (MB) (71 males and 47 females). All of them accepted the new treatment (none requested to be preferably put under standard WHO/MDT), no clinical sign which could be considered as a toxic effect of the drug was noted, and none of the patients refused to continue treatment because of any clinical trouble. The compliance was excellent: the 113 patients (PB and MB) detected during the first 6 months of the trial have taken six monthly doses in 6 months, as planned. The rate of clearance and the progressive decrease of cutaneous lesions was satisfactory. Although it is too soon to give comprehensive results, it should be noted that no treatment failure was observed in the 56 PB patients who have completed treatment and have been followed up for 6 months. The long-term efficacy of the new regimen is to be evaluated on the rate of relapse during the years following the cessation of treatment. If that relapse rate is acceptable (similar to that observed in patients after treatment with current standard WHO/ MDT), the new regimen could be a solution to treat, for instance, patients very irregular and/or living in remote or inaccessible areas since no selection of rifampin-resistant Mycobacterium leprae should be possible (a monthly dose of ofloxacin and minocycline being as effective as a dose of dapsone and clofazimine taken daily for 1 month). Nevertheless, until longer term results of this and other trials become available, there is no justification for any change in the treatment strategy, and all leprosy patients should be put under standard WHO/MDT. (AU)^ien.
Descritores:Hanseníase/quimioter
Rifampina/admin
Rifampina/ef adv
Rifampina/uso terap
Ofloxacino/admin
Ofloxacino/ef adv
Ofloxacino/uso terap
Minociclina/admin
Minociclina/ef adv
Minociclina/uso terap
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  2 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27120
Autor:Katoch, Kiran; Ramanathan, Usha; Natrajan, Mohan; Bagga, Ashok K; Bhatia, AS; Saxena, RK; Ramu, Gopal.
Título:Relapses in paucibacillary patients after treatment with three short term regimens containing rifampin.
Fonte:Int J Lepr;57(2):458-464, June 1989. ^btab.
Resumo:Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment^ien.
Descritores:Dapsona/admin
Dapsona/uso terap
Rifampina/admin
Rifampina/uso terap
Hanseníase/microbiol
Hanseníase/patol
Limites:Humanos
Masculino
Feminino
Adulto
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a02.pdf - en.
Localização:Br191.1


  3 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:19791
Autor:Salafia, A; Ignatia.
Título:Tratamiento intermitente con rifampicina contra tratamiento intensivo en lepra.
Fonte:Fontilles - Revista de Leprología;16(5):585-590, May.-Ago. 1988. tab.
Resumo:Los autores informan y comparan los resultados obtenidos con tratamiento intensivo e intermitente con rifampicina en 244 pacientes. (AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/prev
RIFAMPINA/admin
RIFAMPINA/ef adv
Meio Eletrônico: - .
Localização:BR191.1


  4 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:19026
Autor:Salafia, A; De Geiking, I.
Título:Neuritis and rifampicin.
Fonte:Fontilles - Revista de Leprología;19(6):635-638, Sep.Dic. 1994. .
Resumo:The authors present their observation of neuritis precipited or by RFM in 20 patients all hospitalized except three. The authors belive that, as per literature, none of the drugs used in the MDT programs reach the nerves, however once a nerve is damaged by ischemia, drug to penetrate and can cause further damage; this explains why many patients asymptomatic before therapy, complain of neural pain after starting the therapy. (AU).
Descritores:HANSENIASE
RIFAMPINA/admin
RIFAMPINA/uso terap
NEURITE/quimioter
Meio Eletrônico: - .
Localização:BR191.1


  5 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:19007
Autor:Terencio de las Aguas, José; Gómez Achevarría, José Ramón; López Pla, Jorge.
Título:Efectos secundarios y toxicidad de la rifampicina en el tratamiento de la lepra.
Fonte:Fontilles - Revista de Leprología;19(3):259-267, Sep.-Dic. 1993. ilus.
Resumo:Se analisa la toxicidad y los efectos de la rifampicina en el tratamiento de la lepra. En una experiencia terapéutica sobre 131 enfermos se ha observado una buena tolerancia general citándose algunas alteraciones gastro-intestinales y únicamente cuando se empleó como monoterapia la aparición de reacción lepromatosa en un 60%. Cuando se utilizó asociada a la clofazimina fueron escasos los episódios reaccionales. La tolerancia fue buena incluso asociada al isoprodian. En administración intermitente, mensual o semanal, hubo aparición del "Flu síndrome" en un 25% y 2 casos graves de insuficiencias renales agudas y una hepatitis tóxica. (AU).
Descritores:RIFAMPINA/admin
RIFAMPINA/ef adv
RIFAMPINA/tox
HANSENIASE/compl
HANSENIASE/quimioter
HANSENIASE/prev
Meio Eletrônico: - .
Localização:BR191.1


  6 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18952
Autor:Murray, Clinton K; Joyce, M. Patricia; Longfield, Robert N
Título:Short report: treatment failure in Hanse´n's disease
..-
Fonte:s.l; s.n; 2003. 2 p. tab.
Resumo:Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen's disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen's disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices. (AU).
Descritores:CLOFAZIMINA/admin
DAPSONA/admin
QUIMIOTERAPIA COMBINADA
HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/patol
HANSENIASE/prev
REGISTROS MEDICOS
RECIDIVA
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
TEXAS/epidemiol
FALHA DE TRATAMENTO
RECUSA DO PACIENTE AO TRATAMENTO
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 09084/s


  7 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18672
Autor:Terencio de las Aguas, José.
Título:Multiterapia isoprodian-rifampicina.
Fonte:Fontilles - Revista de Leprología;16(1):11-, Ene.-Abr. 1987. .
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/farmacol
RIFAMPINA/uso terap
Localização:BR191.1


  8 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18645
Autor:Alvarenga, Arnaldo; Leguizamón, Oscar; Frutos, Victoria; Von Ballestrem, Wolfgang.
Título:Tratamiento combinado con rifampicina e isoprodian en lepra, en Paraguay.
Fonte:Fontilles - Revista de Leprología;15(1):11-24, Ene.-Abr. 1985. tab, graf.
Resumo:Se hace un análises de los resultados obtenidos en 789 pacientes de lepra sometidos a un tratamiento con la combinación RMP e IPD que nos permite afirmar sobre su buena tolerancia, eficacia y aceptabilidad, ya que al cabo de 4 años tenemos a 59 por ciento de ellos en etapa de control post-tratamiento, sin señales de recaída ninguno. Efectos colaterales se presentaron en el 14 por ciento del total, principalmente en relación al área gástrica, epro de orden pasajero. El 33 por ciento de los casos L y B hizo reacción del tipo ENL, de los que el 94 por ciento lo fueron de carácter leve, manejable con éxito con talidomida. Hepatitis con ictericia se vio en el 2 por ciento, (16 casos) siendo que en todos ellos se superó dicha situación con la sola interrupción de la terapia, sin dejar secuelas. En quienes hubo necesidad de reanudarla, se tomaron de nuevo sin inconvenientes hasta su finalización. Fueron registrados 5 fallecidos por causas no relacionadas a la terapia combinada. Cabe señalar la rapidez de la mejoría clínico-bacterilógico, ya bien evidente hacia los seis primeros meses de tratamiento, lo cual reviste indudable trascendencia epidemiológica. El programa con RMP e IPD sigue en ejecución. (AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/terap
RIFAMPINA/admin
RIFAMPINA/imunol
PARAGUAI/epidemiol
Localização:BR191.1


  9 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18489
Autor:Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael
Título:Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia
Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia-
Fonte:s.l; s.n; set.-out. 2002. 8 p. tab.
Resumo:The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
DAPSONA/admin
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENIASE/quimioter
COOPERACAO DO PACIENTE/estatíst
DESISTÊNCIA DO PACIENTE/estatíst
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
RIFAMPINA/ef adv
Limites:PRÉ-ESCOLAR
CRIANÇA
ADOLESCENCIA
ADULTO
RESUMO EM INGLES
FEMININO
HUMANO
LACTENTE
RECEM-NASCIDO
MASCULINO
MEIA-IDADE
Localização:BR191.1; 09017/s


  10 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18476
Autor:Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo
Título:Biochemical and hematological side effects of clofazimine in leprosy patients
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Resumo:Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU).
Descritores:CONTAGEM DE CELULAS SANGUINEAS
CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/ef adv
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/ef adv
RIFAMPINA/uso terap
Limites:SUPPORT, NON-U.S. GOV'T
FEMININO
HUMANO
MASCULINO
Meio Eletrônico: - .
Localização:BR191.1; 08998/s


  11 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18448
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; dec. 1983. 3 p. .
Resumo:The treatment of leprosy with sulfones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Leprosarium, Malaysia.(AU).
Descritores:QUIMIOTERAPIA COMBINADA
DAPSONA/admin
RIFAMPINA/admin
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
HANSENIASE/quimioter
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 01651/s


  12 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18334
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; 1983. 3 p. .
Resumo:The treatment of leprosy with sulphones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Lperosarium, Malaysia. (AU).
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
QUIMIOTERAPIA COMBINADA
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
DAPSONA/admin
Limites:HUMANO
Localização:BR191.1; 04896/s


  13 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18312
Autor:Qunibi, Wajeh Y; Godwin, John; Eknoyan, Garabed
Título:Toxic nephropathy during continuous rifampin therapy
..-
Fonte:s.l; s.n; jun. 1980. 2 p. tab.
Resumo:A relatively mild nonoliguric acute renal failure developed early in the course of daily rifampin treatment in a 54-year-old man who was receiving concomitant steroid therapy. The renal lesion was an acute interstitial nephritis characterized by tubular dysfunction:inability to concentrate urine, increase in fractional excretion of sodium and uric acid, and glycosuria with normal blood glucose values. All abnormalities resolved promptly upon withdrawal of rifampin while steroid therapy was gradually reduced. The documents the fact that rifampin-induced nephropathy can occur in the course of a continuous daily regimen and may be favorably influenced by steroid administration.(AU).
Descritores:QUIMIOTERAPIA COMBINADA
INSUFICIÊNCIA RENAL AGUDA/ind quim
PREDNISONA/admin
PREDNISONA/uso terap
RIFAMPINA/admin
RIFAMPINA/ef adv
FATORES DE TEMPO
TUBERCULOSE PULMONAR/quimioter
Limites:RELATO DE CASO
HUMANO
MASCULINO
MEIA-IDADE
Meio Eletrônico: - .
Localização:BR191.1; 00442/s


  14 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18232
Autor:Waters, M. F; Rees, R. J; Pearson, J. M; Laing, A. B; Helmy, H. S; Gelber, R. H
Título:Rifampicin for lepromatous leprosy: nine years' experience
..-
Fonte:s.l; s.n; January 21, 1978. 4 p. tab.
Resumo:Over 100 patients with lepromatous leprosy were treated with rifampicin in a series of pilot, uncontrolled, and controlled trials in 1968-77. The rapid bactericidal effect of rifampicin on Mycobacterium leprae was confirmed. Clinical improvement became apparent sometimes as early as 14 days after the start of treatment. Nevertheless, a few persisting viable M leprae were detected as long as five years after the start of treatment with rifampicin either by itself or in combination with the bacteriostatic drug thiambutosine. Treatment with rifampicin and dapsone for six months reduced the number of persisting leprosy bacteria more than treatment with dapsone alone. Although rifampicin proved more effective than dapsone, it is unlikely that used by itself if can significantly shorten the length of treatment in lepromatous leprosy. Therefore initial intensive combined treatment with two or more bactericidal drugs (including rifampicin) warrants further investigation in both untreated leprosy and lepromatous leprosy resistant to dapsone.(AU).
Descritores:MYCOBACTERIUM LEPRAE/ef drogas
HANSENIASE/quimioter
ENSAIOS CLINICOS
COMBINACAO DE MEDICAMENTOS
DAPSONA/uso terap
FENILTIOUREIA/analog
FENILTIOUREIA/uso terap
RIFAMPINA/admin
RIFAMPINA/farmacol
RIFAMPINA/uso terap
Limites:HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01449/s


  15 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18205
Autor:Pilheu, J. A; De Salvo, Maria de C; Barcat, J. A
Título:Acción de los esquemas con isoniacida y rifampicina sobre el hígado de enfermos tuberculosos
Effect of isoniazid and rifampicin regimens on the liver of tuberculosis patients-
Fonte:s.l; s.n; May-Jun. 1979. 7 p. tab.
Resumo:Se estudió un grupo de 86 enfermos tuberculosos que recebieron esquemas terapèuticos con Isoniacida y Rifampicina y se evaluó la acción de esas drogas sobre el hígado. Para ello, antes de iniciar la quimioterapia, se praticó una biopsia hepática y se dosaron transaminasas, fosfatasa y bilirrubina séricas; al finalizar el tercer mes de tratamiento se repitió una biopsia hepática. Los tests funcionales se repitieron mensualmente durante todo el tratamiento. El grupo I (10 casos) recibió Isonacida, Ethambutol y Estreptomicina. En la biopsia inicial hubo 1 caso con transformación grasa y 1 con necrosis focal; al 3er. mes persistía la necrosis focal en 1 caso y apreció en otros 3. El grupo II (14 casos) recibió Rifampicina, Ethambutol y Capreomicina.(AU).
Descritores:QUIMIOTERAPIA COMBINADA
ETAMBUTOL/uso terap
ISONIAZIDA/admin
ISONIAZIDA/farmacol
ISONIAZIDA/uso terap
RIFAMPINA/admin
RIFAMPINA/farmacol
RIFAMPINA/uso terap
FIGADO/patol
Limites:HUMANO
MASCULINO
FEMININO
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 00140/s


  16 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18179
Autor:Shepard, Charles C; Walker, Laura L; Van Landingham, Rosalind M; Redus, Martha A
Título:Kinetic testing of drugs against Mycobacterium leprae in mice. Activity of cephaloridine, rifampin, streptovaricin, vadrine, and viomycin
..-
Fonte:s.l; s.n; jul. 1971. 5 p. tab, graf.
Resumo:A series of drugs that had been found active against Mycobacterium leprae in mice by the continous method of drug administration was tested by the kinetic method. Vadrine and vyomivin were found inactive. Cephaloridine, streptovaricin, and rifampin gave bactericidal-type results. In a second experiment, rifampin was found to have distinct bactericidal effect when given for only 2 days. The plasma levels of rifampin that were associated with bactericidal effect in mice were in the range reported for man receiving acceptable dosages of rifampin. Cephaloridine and, especially, rifampin merit further investigation in clinical trials in leprosy patients, either as single drugs or in combination with other active drugs. The combination of rifampin and dapsone (DDS) or acedapsone (DADDS) appear to provide the advantages of tboth drugs.(AU).
Descritores:ANTIMALARICOS/admin
DAPSONA/admin
INJECOES SUBCUTÂNEAS
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE/ef drogas
MYCOBACTERIUM LEPRAE/cresc
RIFAMPINA/admin
RIFAMPINA/sangue
VIOMICINA/admin
DIETA
 ESTUDOS DE AVALIACAO
 CINETICA
 MALARIA/sangue
 OXIDIAZOIS/admin
 PIRIDINAS/admin
 ACIDOS SALICILICOS/admin
 ESTREPTOVARICINA/admin
Limites:ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 02305/s


  17 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18041
Autor:Shepard, Charles C; Levy, Louis; Fasal, Paul
Título:Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae
..-
Fonte:s.l; s.n; nov. 1974. 5 p. tab, graf.
Resumo:The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients lesions. In a trial of rifampin in a dosage of 600mg daily, the bacterial viability feel to undectable levels in the first specimen taken after the start of theraphy (at 3-4 days in 4 patients, 7-8 days in 9, and 4 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3-5 days in all 14 patients).(AU).
Descritores:FATORES DE TEMPO
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE/ef drogas
DAPSONA/admin
DAPSONA/farmacol
ENSAIOS CLINICOS
RELACAO DOSE-RESPOSTA A DROGA
BIOPSIA
RIFAMPINA/admin
RIFAMPINA/farmacol
Limites:HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01966/s


  18 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17947
Autor:Ramu, G; Sreevatsa; Sengupta, U; Desikan, K. V
Título:Evaluation of multiple regimens in leprosy
..-
Fonte:s.l; s.n; apr. 1981. 7 p. tab, graf.
Resumo:Assessment of bacteraemia has been made at weekly intervals in 36 lepromatous leprosy patients who were put on different antileprosy drug under four regimens, viz., DDS alone, DDS in combination with rifampicin (DDS + RIF), clofazimine (DDS + CLF) and thiacetazone (DDS + TCT). In general, with the continuation of treatment the bacillary load in the blood decreased considerably while bacteriological index (BI) of the skin remained constant during the study. No significant difference was noted in M. leprae clearance from blood between the groups treated with DDS alone and groups treated in combination with CLF and TCT. However, DDS + RIF treatment was most efficient in clearing acid-fast bacilli (AFB) from blood as compared to those noted with other drug regimens.(AU).
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
SEPTICEMIA/quimioter
QUIMIOTERAPIA COMBINADA
DAPSONA/ef adv
TIOACETAZONA/admin
CLOFAZIMINA/admin
AVALIACAO DE MEDICAMENTOS
Limites:ESTUDO COMPARATIVO
HUMANO
MASCULINO
Meio Eletrônico: - .
Localização:BR191.1; 00696/s


  19 / 43 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17851
Autor:Dey, S. K; Chanda, M; Chowdhury, A; Panja, S. K
Título:Treatment of paucibacillary leprosy by WHO regimen
..-
Fonte:s.l; s.n; jan. 1987. 3 p. .
Resumo:50 Cases of paucibacillary leprosy was selected for study multi-drug therapy recommended by W.H.O. for sixth months. At the end of six months, 46 cases showed "no clinical activity" and 4 cases showed increased clinical activityweth flaring up of the lesions during treatment.(AU).
Descritores:DAPSONA/admin
DAPSONA/uso terap
COMBINACAO DE MEDICAMENTOS
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/uso terap
ORGANIZACAO MUNDIAL DA SAUDE
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 02084/s


  20 / 43 HANSEN  
              first record previous record
seleciona
para imprimir
Id:17839
Autor:Bourée, P; Carré, N; Drahmane, S
Título:Guinée: dépistage de la lèpre et traitement par polychimiothérapie
Guinea: detection of leprosy and treatment by polychemotherapy-
Fonte:s.l; s.n; 1988. 9 p. mapas, tab.
Resumo:Since a year, the implementation of multidrug therapy on leprosy control in Guinea has been needing a good cooperation between Department of Leprosy Control and local nurses. The known prevalence, in the area of Pita is 1.23%. 246 patients has been detected: 36 multibacillary and 210 paucibacillary. The sex-ratio of the patients has changed, during one year, toward the men. With the sensitivity of the local population, number of detected cases is increasing and the rate of regular attendance at treatment is correct in 87.6% of cases.(AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/epidemiol
RIFAMPINA/admin
RIFAMPINA/uso terap
AFRICA OCIDENTAL
CLOFAZIMINA/admin
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
Limites:HUMANO
MASCULINO
FEMININO
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 02055/s



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information